Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Title Preview of Cardlytics Quarterly Earnings Report and Stock Performance

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
Finance_ People trading stocks
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Cardlytics, a leading company in the financial sector, is set to unveil its quarterly earnings report on March 14, 2024. Analysts are predicting an EPS of $0.12 for the company. It is essential for investors to not only focus on whether Cardlytics surpasses this estimate but also on any positive guidance given for the next quarter, as this can have a significant impact on stock prices.

Looking back, Cardlytics fell short of its EPS estimate last quarter, resulting in a sharp 54.45% decline in share price the following day. However, over the past 52 weeks, Cardlytics shares have shown a promising upward trend, with a 157.57% increase, reflecting optimism among long-term shareholders. As of March 12, shares of Cardlytics were trading at $8.65.

In the third quarter of 2023, Cardlytics reported revenue of $79.0 million, with year-over-year increases in various metrics. For the fourth quarter of 2023, Cardlytics is expecting billings, revenue, adjusted contribution, and adjusted EBITDA to fall within specific ranges. The average price target for Cardlytics Inc is $12.50 based on three Wall Street analysts’ 12-month price targets.

In conclusion, investors should keep a close eye on Cardlytics’s upcoming earnings report to gain insights into its financial performance and future prospects.

CDLX Stock Shows Positive Momentum with 1.27% Increase – Investors Advised to Monitor Performance Closely

On March 13, 2024, CDLX stock showed some positive momentum as it closed the trading day with a 1.27% increase in its share price. Throughout the trading day, the price of CDLX shares increased by $0.11. Despite this increase, CDLX is currently trading in the middle of its 52-week range and below its 200-day simple moving average. Investors may want to keep a close eye on CDLX’s performance in the coming days to see if the positive momentum continues or if the stock experiences a reversal. It is important to consider both short-term price movements and long-term trends when making investment decisions. It is recommended that investors conduct thorough research and analysis before making any investment decisions.

CDLX Stock Performance Analysis: Revenue Up, Net Income Down – March 13, 2024

On March 13, 2024, CDLX stock showed mixed performances based on the financial data provided by CNN Money. The total revenue for the company was reported at $298.54 million for the past year, showing an increase of 11.76% compared to the previous year. The total revenue for the third quarter was $79.00 million, representing a 3.0% increase since the previous quarter.

However, the net income for CDLX was not as positive, with a reported loss of $465.26 million for the past year and a loss of $23.97 million for the third quarter. This represents a significant decrease of 261.89% in net income since the previous year, although there was a slight increase of 1.95% since the previous quarter.

The earnings per share (EPS) for CDLX also showed a decline, with a reported EPS of -$13.92 for the past year and -$0.63 for the third quarter. This represents a decrease of 248.72% in EPS since the previous year, although there was a slight increase of 6.38% since the previous quarter.

Overall, the financial performance of CDLX on March 13, 2024, was a mixed bag. Investors may want to closely monitor future financial reports and company announcements to gauge the company’s financial health and potential for growth in the future.

Tags: CDLX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Altus Power NYSEAMPS Earnings Preview and Performance Analysis

Healthcare-and-IT

Changing Sentiment Towards UnitedHealth Group Stock

Food Retailers Market Capitalization

WilliamsSonoma Surges After Strong Fourth Quarter Results and Dividend Increase

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com